Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

Tesamorelin is the first and only approved treatment for reducing excess abdominal fat in HIV lipodystrophy, significantly reducing visceral adipose tissue over 26 weeks.

Abstract

Tesamorelin (Egrifta™) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone.. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy.. This article reviews the.

Key Findings

It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. | Subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), but did not affect subcutaneous adipose tissue to a clinically significant extent in two 26-week, well designed, clini...

Study Design

Review article